期刊文献+

EGCG逆转人耐药肝癌细胞株多药耐药的体内实验研究 被引量:12

THE MDR-REVERSING EFFECT OF (-)-EPIGALLOCATECHIN-3-GALLATE ON HUMAN HEPATOCELLULAR CARCINOMA BEL-7404/ADR IN VIVO
下载PDF
导出
摘要 目的:研究表没食子儿茶素没食子酸酯(EGCG)体内逆转人肝癌细胞多药耐药性的作用及可能的机制。方法:MTT法检测肝癌耐药细胞株BEL-7404/ADR与其亲本细胞BEL-7404耐药倍数,采用BEL-7404/ADR种植于裸鼠皮下,建立肿瘤耐药模型,两周后EGCG灌胃,腹腔注射阿霉素(ADM),联合治疗两周;荧光分光光度法检测瘤体内ADM含量,HE染色观察形态学改变;RT-PCR检测瘤组织mdr1mRNA的表达,免疫组化法检测瘤组织P糖蛋白(P-gp)的表达。结果:低、中、高EGCG联合ADM组肿瘤生长速度明显低于ADM组,瘤重明显低于阿霉素组;EGCG联合ADM可增加瘤体内ADM的含量(P<0·01);三个EGCG联合ADM组与阿霉素组相比HE病理图片显示肿瘤组织纤维包裹,炎细胞浸润;mdr1mRNA和P-gp的表达明显低于对照组和阿霉素组(P<0·01)。结论:EGCG在体内具有逆转BEL-7404/ADR的耐药作用,机制可能是EGCG下调了肝癌细胞mdr1基因的表达,使P-gp的表达降低,瘤组织内药量增高。 Objective.This study aims to investigate the multi-drug resistance reversal effects of (-)-Epigallocatechin-3-gallate (EGCG) on xenografts derived from multi-drug resistant hepatocellular carcinoma (HCC) cell line BEL-7404/ADR and the possible mechanism. Methods:Cell survival rate was determined by MTT assay. The models of BEL-7404/ADR xenograft in nude mice were established and received the desired drug and dosage. Morphology of xenografts were investigated by HE staining. ADM concentration in the tumors was determined with a fluorescence spectrophotometer. The expressions of mdrl and P-glycoprotein(P-gp) were observed with reverse transcriptase PCR and immunohistochemistry respectively. Resalt: In the models of BEL-7404/ADR xenografts, the growth rates of the three co-adminstration group were lower than that of ADM group. EGCG of 40 mg/kg,80 mg/kg,160 mg/kg,exhibited (56.7%,62.2%, 65.1%) in inhibiting the growth of xenografts, respectively. ADM Concentration in the tumors of the three co-administration groups were higher than ADM group. The combination of EGCG and ADM reduced the expression of mdrl and P-gp( P 〈0.01) . Conclusion: EGCG can reverse the multi-drug resistance of human HCC in vivo. The mechanism is probably associated with down-regulating the expression of mdrl and P-gp.
出处 《广西医科大学学报》 CAS 北大核心 2006年第1期8-11,共4页 Journal of Guangxi Medical University
基金 广西自然科学基金资助(No.0004302)
关键词 表没食子儿茶素没食子酸酯 多药耐药 P糖蛋白 肝细胞癌 多药耐药逆转剂 EGCG multi-drug resistance P-glycoprotein hepatocellular carcinoma reversal agents
  • 相关文献

参考文献8

二级参考文献31

  • 1赵跃武,刘政国,孔令非,王宝梅,银平章.32例肝癌组织中多药耐药基因及其产物P-糖蛋白的实验研究[J].中国民康医学,1998,13(3):150-151. 被引量:4
  • 2隋延仿,刘利,陈志南,刘彦仿,王文亮.肝癌“双弹头”组合单抗导向治疗的实验研究[J].中国肿瘤临床,1995,22(10):736-740. 被引量:9
  • 3晁红霞 孙建衡.DNA甲基化与肿瘤[J].国外医学:肿瘤学分册,1999,26:134-136.
  • 4金正均.合并用药中的相加[J].中国药理学报,1980,1:70-73.
  • 5汤钊猷 刘康达 等.肝癌导向治疗研究12年(1983-1995)总结[J].上海医科大学学报,1995,22:1-13.
  • 6Epenetos AA . Antibody-guided irradiation of advanced ovarian cancer with intraperitoneal ly administered radiolabeled monoclonal antibodies.J Clan Oncol,1987,5:1 890.
  • 7Van Zanten Przybysz I, Molthoff CF, Roos JC, et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOV 18:i.V.Vs.i.P.Int J Cancer,2001,92(1):106-114.
  • 8Turner JH,Rose AH,Glancy RJ,et al.Orthotopic xenog-rafts of human melonoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy. Br J cancer,1998,78(4):486-494.
  • 9Goldenberg DM.Targeted therapy of cancer with radiol-abeled antibodies. J Nucl Med,2002,43(5):693-713.
  • 10吴英德 宋向群 周德南.131I(或125I)——抗AFP抗体导向治疗肿瘤的临床研究[J].中国肿瘤临床,1995,22(10):736-740.

共引文献36

同被引文献163

引证文献12

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部